SPRB Reports $10.2M 2025 Revenue, $0.02 EPS, +120% YoY; BLA Submission Q4 2026; $50M Growth Capital; Dale Hooks CCO; TA-ERT Shows 90% CSF HS Reduction; PRV Extended to 2029
Spruce Biosciences, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $50.70
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS